Login to Your Account

Genzyme, BioMarin Receive FDA's Aldurazyme Approval

By Kim Coghill

Thursday, May 1, 2003
Genzyme General and its partner, BioMarin Pharmaceutical Inc., received FDA approval for Aldurazyme, an enzyme replacement therapy for the treatment of a rare degenerative disease, mucopolysaccharidosis-1. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription